LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Market Sentiment | Analysts maintain "Market Perform" rating. Stock undervalued per InvestingPro, despite 87% drop over past year. Average price target not provided |
Strategic Crossroads | Explore Athira's pursuit of partnerships and alternatives to maximize shareholder value amidst drug development challenges and market skepticism |
Financial Tightrope | Despite $30M cash reserves, Athira faces a high burn rate. Market cap at $14.6M reflects investor caution, trading at 48% of cash position |
ALS Breakthrough | Athira Pharma's ATH-1105 shows promise in ALS treatment, with plans for a biomarker-focused study in late 2025 following positive Phase 1 results |
Metrics to compare | LONA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLONAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.8x | −5.8x | −0.5x | |
PEG Ratio | −0.41 | −0.01 | 0.00 | |
Price / Book | 3.2x | 1.9x | 2.6x | |
Price / LTM Sales | - | 5.6x | 3.2x | |
Upside (Analyst Target) | 76.4% | 155.9% | 45.7% | |
Fair Value Upside | Unlock | 12.5% | 4.8% | Unlock |